Announcements Trials
Browse Landscape

Status

No longer available 2Approved for marketing 2

Sponsor Class

OTHER 4

Study Type

Interventional 97Observational 5Expanded_access 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Prostatic Diseases 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Expanded_access × gallium 68 PSMA-11 × Clear all
NCT05002465 2023-09-11

Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer

University of Texas Southwestern Medical Center

No longer available
Genitourinary

Prostatic Neoplasms

NCT05415228 2023-05-18

Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer

University of Michigan

No longer available
Genitourinary

Prostatic Neoplasms

NCT04452136 2022-03-14

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

OHSU Knight Cancer Institute

Approved for marketing
Genitourinary

Prostatic Diseases, Prostatic Neoplasms

NCT04377152 2021-03-01

Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer

University of California, San Francisco

Approved for marketing
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡